Sign up to save your podcasts
Or
Share [Korean Startup Interview] AbFinder Therapeutics Tackles ADC Challenges with Its PepFc Innovation
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
[Korean Startup Interview] AbFinder Therapeutics Tackles ADC Challenges with Its PepFc Innovation
https://en.wowtale.net/2025/06/04/231246/
This interview with AbFinder Therapeutics from WOWTALE highlights the company's innovative PepFc technology, designed to overcome significant challenges in antibody-drug conjugate (ADC) development. The article explains how AbFinder aims to improve cancer treatments by addressing issues like antibody miniaturization for better tumor penetration, half-life extension to ensure drug longevity, and toxicity reduction by eliminating harmful interactions. It details AbFinder's B2B business model, offering PepFc licensing, antibody discovery services, and proprietary pipeline development, positioning the company as a key player in the evolving biopharma market. The text emphasizes the team's expertise and the market potential for their solutions in both cancer and other therapeutic areas.
View all episodes
By WOWTALEhttps://en.wowtale.net/2025/06/04/231246/
This interview with AbFinder Therapeutics from WOWTALE highlights the company's innovative PepFc technology, designed to overcome significant challenges in antibody-drug conjugate (ADC) development. The article explains how AbFinder aims to improve cancer treatments by addressing issues like antibody miniaturization for better tumor penetration, half-life extension to ensure drug longevity, and toxicity reduction by eliminating harmful interactions. It details AbFinder's B2B business model, offering PepFc licensing, antibody discovery services, and proprietary pipeline development, positioning the company as a key player in the evolving biopharma market. The text emphasizes the team's expertise and the market potential for their solutions in both cancer and other therapeutic areas.